All In Biotech

Drug Trial Radar · NCT03268902

Early Life Interventions for Childhood Growth and Development In Tanzania

Last checked: Nov 20, 2026Latest source record: May 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,188 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,188

Actual

Start

Sep 5, 2017

Primary completion

Feb 28, 2020

Study completion Mar 26, 2020

Sponsor

Lead sponsor
Haydom Lutheran HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Virginia; Bill and Melinda Gates Foundation
First posted
Aug 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 days, up to 14 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to assess growth and cognitive effects of treatment with azithromycin and nitazoxanide and/or nicotinamide (vitamin B3) supplementation nicotinamide.

Conditions

  • Malnutrition
  • Stunting
  • Cognitive Development
  • Enteric Pathogens

Interventions

  • Azithromycin Oral Liquid ProductDrug

    Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months

  • Nitazoxanide Oral SuspensionDrug

    Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months

  • NicotinamideDietary supplement

    Mothers in the nicotinamide arm will be given nicotinamide 250 mg daily from delivery through 6 months post-partum in capsule form. Children in the nicotinamide arm will be given 100 mg/d in powder form between 6 and 18 months of age

  • PlacebosDrug

    Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months. Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form. Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Height-for-age z-score (HAZ) at 18 monthsTime frame: 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Haydom Lutheran Hospital

    Haydom, Manyara Region, Tanzania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.